Mizuho Securities Buyers of Biohaven Pharmaceutical (BHVN) on Weakness

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. CVS

Go back to Mizuho Securities Buyers of Biohaven Pharmaceutical (BHVN) on Weakness

Biohaven Pharma (BHVN) Reports OCD Proof Of Concept Phase 2/3 Study Results And Program Update

June 24, 2020 7:04 AM EDT

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today reported topline results from its proof of concept study of troriluzole in the treatment of obsessive-compulsive disorder (OCD).

Table 1 shows the mean change in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) total score over time. Troriluzole treated subjects had a mean Y-BOCS improvement of -5.1 points from baseline versus -3.6 for placebo-treated subjects [difference -1.5, p-value=0.041, 95% CI: -3.02, -0.06] at week 8, and -5.9 points versus -4.9 for placebo subjects [difference -1.0, p-value = 0.220, 95% CI: -2.59, 0.60] at week 12. Although the p-value in this proof of concept study did not... More